Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114555 | 0.96 | HSD17B10 (0.55) | MEN1KMT2AHDAC6KDM4EALDH1A1 | |
| Water SCHEMBL8122300 | 0.94 | HSD17B10 (0.54) | MEN1KMT2AHDAC6KDM4EALDH1A1 | |
| SCHEMBL10123163 | 0.83 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10TLR7NCF1 | |
| SCHEMBL12888414 | 0.83 | NCF1 (0.47) | KDM4EALDH1A1ALOX15HSD17B10USP2 | |
| Hydrochloric Acid SCHEMBL1233122 | 0.81 | TLR7 (0.40) | KDM4EALDH1A1ALOX15HSD17B10USP2 | |
| SCHEMBL1233115 | 0.79 | ALDH1A1 (0.39) | MEN1KMT2AHDAC6KDM4EALDH1A1 | |
| SCHEMBL8114384 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10TLR7NCF1 | |
| Hydrochloric Acid SCHEMBL1233645 | 0.77 | NCF1 (0.44) | KDM4EALDH1A1ALOX15HSD17B10TLR7 | |
| SCHEMBL202353 | 0.77 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL1231786 | 0.77 | TLR7 (0.40) | KDM4EALDH1A1ALOX15HSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-23 | — | — | US | claimed |
| EP-0802913-B1 | IMIDAZO [4,5-c]QUINOLINE AMINES | MINNESOTA MINING & MFG (US) | 2000-04-26 | — | — | EP | claimed |
| US-5482936-A | INDUCE INTERFERON BIOSYNTHESIS IN AN ANIMAL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-01-09 | — | — | US | claimed |
| EP-3889158-B1 | FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-03 | — | — | EP | disclosed |
| US-8110582-B2 | by administering immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-07 | — | — | US | disclosed |
| US-7968562-B2 | an immune response modifier (IRM) compound 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine; fatty acids such as oleic acid, isostearic acid; hydrophobic, aprotic caprylic/capric triglyceride miscible with fatty acid; actinic keratosis, postsurgical scars, warts, atopic dermatitis | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1450804-B9 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1719511-B1 | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080275077-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | SKWIERCZYNSKI RAYMOND D | 2008-11-06 | — | — | US | disclosed |
| EP-1450804-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1719511-A2 | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof | 3M Innovative Properties Company (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20040175336-A1 | Prophylactic treatment of UV-induced epidermal neoplasia | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
| EP-0802913-B1 | IMIDAZO [4,5-c]QUINOLINE AMINES | MINNESOTA MINING & MFG (US) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199538-A1 | Pharmaceutical formulation comprising an immune response modifier | ICOS, STAT6, INMT | MEN1 4850/4885KMT2A 419/4885HDAC6 2584/4885 |
| US-20080275077-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER | ICOS, STAT6, INMT | MEN1 4853/4885KMT2A 396/4885HDAC6 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.